Koh Jeong Suk, Song Ik-Chan
Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Hospital, 282 Munwha-Ro, Jung-Gu, Daejeon, 35015, South Korea.
Blood Res. 2024 Aug 7;59(1):26. doi: 10.1007/s44313-024-00030-w.
Anemia is frequently observed in patients with cancer owing to anticancer chemotherapy, radiation therapy, and inflammatory responses. This often leads to functional iron deficiency, characterized by adequate iron stores but impaired use of iron for red blood cell production. This condition, termed functional iron deficiency anemia (IDA), is identified by a ferritin level of 30-500 µg/dL and a transferrin saturation < 50%. Functional iron deficiency often develops with the prolonged use of erythropoiesis-stimulating agents, leading to a diminished response to anemia treatment. Although oral iron supplementation is common, intravenous iron is more effective and recommended in such cases. Recent studies have shown that ferric carboxymaltose (FCM) is effective in treating functional IDA in patients with cancer. However, because of its potential to induce asymptomatic severe phosphate deficiency, it is important to closely monitor phosphate levels in patients receiving FCM.
由于抗癌化疗、放射治疗和炎症反应，贫血在癌症患者中很常见。这通常会导致功能性缺铁，其特征是铁储存充足，但用于红细胞生成的铁利用受损。这种情况被称为功能性缺铁性贫血（IDA），通过铁蛋白水平为30-500µg/dL和转铁蛋白饱和度<50%来确定。功能性缺铁通常随着促红细胞生成素的长期使用而发生，导致对贫血治疗的反应减弱。虽然口服铁补充剂很常见，但在这种情况下静脉注射铁更有效且被推荐。最近的研究表明，羧麦芽糖铁（FCM）在治疗癌症患者的功能性IDA方面是有效的。然而，由于其可能诱发无症状的严重磷缺乏，密切监测接受FCM治疗的患者的磷水平很重要。
